ArticleInfection and drug resistance2026
MiR-181a, IL-6, and TNF-α: Biomarkers for Diagnosis and Long-Term Neurodevelopmental Prognosis in Neonatal Sepsis.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the value of serum microRNA-181a (miR-181a), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) in early prediction of neonatal sepsis and their correlation with long-term neurodevelopmental outcomes. Methods: A retrospective analysis of 131 septic and 129 non-infected neonates from January 2023 to August 2024 assessed serum miR-181a, TNF-α, and IL-6 levels, with neurodevelopmental outcomes evaluated at 12 months. Multivariate logistic regression was employed to identify risk factors for sepsis and adverse neurodevelopmental outcomes. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive value of each indicator for sepsis and poor neurodevelopmental outcomes. Results: The septic group had lower miR-181a and higher IL-6 and TNF-α levels (P < 0.0001), with an AUC of 0.860 for sepsis diagnosis. Among septic neonates, 31.30% had neurodevelopmental abnormalities, linked to lower miR-181a and higher IL-6 and TNF-α levels (P < 0.01), with an AUC of 0.850 for predicting these abnormalities. Multivariable logistic regression identified miR-181a as a protective factor for neonatal sepsis, while IL-6, TNF-α, and NLR were independent risk factors. For long-term adverse neurodevelopmental outcomes, miR-181a and gestational age served as protective factors, whereas IL-6, TNF-α, and prenatal inflammation were independent risk factors. Conclusion: Serum miR-181a, IL-6, and TNF-α are sensitive indicators for the early prediction of neonatal sepsis. Low expression of miR-181a and high expression of IL-6 and TNF-α are closely associated with adverse neurodevelopmental outcomes. Combined detection of these three markers holds significant clinical value for prognostic assessment, facilitating early identification of high-risk infants and enabling timely intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.